Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice

Oncology Research

Volumn 11, Issue 1, 1999, Pages 33-39

  Arab, Sara ^a   Rutka, James ^b,d   Lingwood, Clifford ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Antineoplastic; Glioblastoma multiforme; Globotriaosyl ceramide

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; CYTOTOXIN; VEROTOXIN 1;

ANIMAL; APOPTOSIS; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MOUSE; NUDE MOUSE; PATHOLOGY; VASCULARIZATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTOMA; BACTERIAL TOXINS; BRAIN NEOPLASMS; CYTOTOXINS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; SHIGA-LIKE TOXIN I; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032603531     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Karmali, M. A. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2:15-38; 1989.
2. Karmali, M. A.; Petric, M.; Lim, C.; Fleming, P. C.; Arbus, G. S.; Lior, H. The association between hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coll. J. Infect. Dis. 151:775-782; 1985.
3. Riley, L. W. Hemorrhagic colitis - a "new" disease. Clin. Microbiol. Newsletter 7:47-49; 1985.
4. Farkas-Himsley, H.; Rosen, B.; Hill, R.; Arab, S.; Lingwood, C. A. Bacterial colicin active against tumour cells in vitro and in vivo is verotoxin 1. Proc. Natl. Acad. Sci. USA 92:6996-7000; 1995.
5. Arab, S.; Murakami, M.; Dirks, P.; Boyd, B.; Hubbard, S.; Lingwood, C.; Rutka, J. Verotoxins inhibit the growth of and induce apotosis in human astrocytoma cells. J. Neurol. Oncol. 40:137-150; 1998.
6. Mangeney, M.; Lingwood, C. A.; Caillou, B.; Taga, S.; Tursz, T.; Wiels, J. Apoptosis induced in Burkitt's lymphoma cells via Gb3/ CD77, a glycolipid antigen. Cancer Res. 53:5314-5319; 1993.
7. Williams, J. M.; Lea, N.; Lord, J. M.; Roberts, L. M.; Milford, D. V.; Taylor, C. M. Comparison of ribosome-inactivating proteins in the induction of apoptosis. Toxicol. Lett. 91:121-127; 1997.
8. Sandvig, K.; Garred, O.; van Helvoort, A.; van Meer, G.; van Deurs, B. Importance of glycolipid synthesis for butyric acid-induced sensitization to Shiga toxin and intracellular sorting of toxin in A431 cells. Mol. Biol. Cell 7:1391-1404; 1996.
9. Wenk, J.; Andrews, P. W.; Casper, J.; Hata, J.-I.; Pera, M. F.; von Keitz, A.; Damjanov, I.; Fenderson, B. A. Glycolipids of germ cell tumors: Extended globo-series glycolipids are a hallmark of human embryonal carcinoma cells. Int. J. Cancer 58:108-115; 1994.
10. Ohyama, C.; Fukushi, Y.; Satoh, M.; Saitoh, S.; Orikasa, S.; Nudelman, E.; Straud, M.; Hakomori, S.-I. Changes in glycolipid expression in human testicular tumors. Int. J. Cancer 45:1040-1044; 1990.
11. Li, S.-C.; Kundu, S. K.; Degasperi, R.; Li, Y.-T. Accumulation of globotriaosylceramide in a case of leiomyosarcoma. Biochem. J. 240:925-927; 1986.
12. Arab, S.; Russel, E.; Chapman, W.; Rosen, B.; Lingwood, C. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol. Res. 9:553-563; 1997.
13. Rutka, J.; Giblin, J.; Hoifodt, H.; Dougherty, D.; Bell, C.; McCullough, J.; Davis, R.; Wilson, C.; Rosenblum, M. Establishment and characterization of a cell line from a human gliosarcoma. Cancer Res. 46:5893-5902; 1986.
14. Arab, S.; Lingwood, C. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin: Sodium butyrate or selection of drug resistance may induce nuclear toxin targeting via globolriosyl ceramide fatty acid isoform traffic. J. Cell. Physiol. 177:646-660; 1998.
15. Boulanger, J.; Huesca, M.; Arab, S.; Lingwood, C. A. Universal method for the facile production of glycolipid/lipid matrices for the affinity purification of binding ligands. Anal. Biochem. 217: 1-6; 1994.
16. Petric, M.; Karmali, M. A.; Richardson, S.; Cheung, R. Purification and biological properties of Escherichia coli verocytotoxin. FEMS Microbiol. Lett. 41:63-68; 1987.
17. Lingwood, C. A. Verotoxin-binding in human renal sections. Nephron 66:21-28; 1994.
18. Krenik, K. D.; Kephart, G. M.; Offord, K. P.; Dunnette, S. L.; Gleich, G. J. Comparison of antifading agents used in immunofluorescence. J. Immunol. Methods 117:91-97; 1989.
19. Gavrieli, Y.; Sherman, Y.; Ben-Sasson, S. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493-501; 1992.
20. Carter, A. O.; Borczyk, A. A.; Carlson, J. A. K.; Harvey, B.; Hockin, J. C.; Karmali, M. A.; Krishnan Korn, D. A.; Lior, H. A severe outbreak of Escherichi coli 0157:H7-associated heinorrhagic colitis in a nursing home. N. Engl. J. Med. 317:1496-1500; 1987.
21. van der Kar, N. C. A. J.; Monnens, L. A. H.; Karmali, M.; van Hinsbergh, V. W. M. Tumor necrosis factor and interleukin-1 induce expression of the verotoxin receptor globotriaosyl ceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 80:2755-2764; 1992.
22. Louise, C. B.; Obrig, T. G. Shiga toxin-associated hemolytic uremic syndrome: Combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect. Immun. 60:1536-1543; 1992.
23. Ramegowda, B.; Tesh, V. L. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect. Immun. 64:1173-1180; 1996.
24. Tesh, V. L.; Ramegowda, B.; Samuel, J. E. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect. Immun. 62:5085-5094; 1994.
25. van Selten, P.; Monnens, L.; Verstraten, R.; van der Heuvel, L.; van Hinsberg, V. Effects of verotoxin-1 on non adherent human monocytes: Binding characteristics, protein synthesis, and induction of cytokine release. Blood 88:174-183; 1996.
26. Tzipori, S.; Chow, C. W.; Powel, H. R. Cerebral involvement with Escherichia coli 0157:117 in humans and gnotobiotic piglets. J. Clin. Pathol. 41:1099-1103; 1988.
27. Siegler, R.; Pysher, T.; Tesh, V.; Taylor, F. Primate response to sinale and divided doses of Shiga-like toxin 1. Pediatr. Nephrol. 12:C74; 1998.
28. Thapar, K.; Fukuyama, K.; Rutka, J. Neurogenetics and molecular biology of human brain tumors. In: Kaye, A.; Laws, E., eds. Brain tumors. Edinburgh: Churchill Livingston; 1995:69-98.
29. McCormack, B.; Miller, D.; Budzilovich, G.; Voorhees, G.; Ransohoff, J. Treatment and survival of low-grade astrocytomas in adults. Neurosurgery 31:636-642; 1992.
30. Wiels, J.; Fellous, M.; Tursz, T. Monoclonal antibody against a Burkilt-Iymphoma-associated antigen. Proc. Natl. Acad. Sci. USA 78:6485-6488; 1981.
31. Pastan, I.; Gottesman, M.; Ueda, K.; Lovelace, E.; Rutherford, A.; Willingham, M. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. USA 85:4486-4490; 1988.
32. Cohen, A.; Hannigan, G. E.; Williams, B. R. G.; Lingwood, C. A. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J. Biol. Chem. 262: 17088-17099; 1987.
33. Lingwood, C. A.; Yiu, S. C. K. Glycolipid modification of α-interferon binding: Sequence similarity between α-interferon receptor and the verotoxin (Shiga-like toxin) B-subunit. Biochem. J. 283:25-26; 1992.
34. Ghislain, J.; Lingwood, C.; Maloney, M.; Penn, L.; Fish, E. Association between the ifn alpha receptor and the membrane glycolipid globotriaosyl ceramide. J. Interferon Res. 12:s114; 1992.
35. 2 based on in vitro sensitivity tests. Clin. Invest. 72:317-320; 1994.
36. Colamonici, O.; Porterfied, B.; Domanski, P.; Handa, R.; Flex, S.; Samuel, C.; Pine, R.; Diaz, M. Ligand-independent anti-oncogenic activity of the alpha subunit of the type I interferon receptor. J. Biol. Chem. 269:27275-27279; 1994.
37. Buckner, J.; Brown, L.; Kugler, J.; Cascino, T.; Krook, J.; Mailliard, J.; Kardinal, C.; Tschetter, L.; O'Fallon, J.; Scheithauer, B. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J. Neurosurg. 82:430-435; 1995.
38. Cherchi, P.; Dessole, S.; Esposito, F.; Ambrosini, G.; El Quanil, F.; Ambrosini, A. Traitement intraperitoneal par l'alpha 2b interferon dans le cancer de l'ovaire avance en remission complete ou avec malade residuelle minime. J. Gynecol. Obst. Biol. Reprod. 25:101-102; 1996.
39. Burger, P. C.; Scheithauer, B. W.; Vogel, F. S. Surgical pathology of the nervous system and its coverings. In: Brain tumors, 3rd ed. New York: Churchill Livingston; 1991:193-437.
40. Boehm, T.; Folkman, J.; Browder, T.; O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407; 1997.
41. Cohen, A.; Madrid-Marina, V.; Estrov, Z.; Freedman, M.; Lingwood, C. A.; Dosch, H.-M. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: A mechanism for the failure of long-lived antibody response to dysenteric disease. Int. Immunol. 2:1-8; 1990.